RecruitingNANCT05377268

The Use of Machine Learning Detection of Lipohypertrophy to Improve Glycemic Variability

Sponsor: University of British Columbia

Trial Details

Condition	Diabetes Mellitus, Lipohypertrophy
Intervention	LH Protocol
Phase	NA
Status	Recruiting
Participants	100
Est. Completion	31 Dec 2026
Last Updated	1 May 2026

Primary Outcome

Assessment of lipohypertrophy by US machine

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Subjects with a diagnosis of Type 1 or Type 2 diabetes mellitus * Current treatment with a minimum of one insulin injection daily or insulin pump for at least 2 years Exclusion Criteria: * Subjects taking a glucagon-like peptide-1 agonist or a systemic glucocorticoid * Past history of a non-lipohypertrophic dermatological condition in the insulin injection site area

Trial Sites

Countries

Canada

View Registry Entry

Related Analysis

Novel Ultrasound Protocol Targets Hidden Lipohypertrophy in Insulin-Dependent Diabetes — Canadian Trial Seeks to Improve Glycemic Control

University of British Columbia researchers are pioneering ultrasound detection of hidden lipohypertrophy at insulin injection sites. This innovative trial uses machine learning to identify subclinical tissue changes that may impair glucose control in diabetes patients.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service